Laurel Oldach's profile photo

Laurel Oldach

Silver Spring

Associate Editor at C&EN

Science writer on the biochemistry and instrumentation beat for C&EN (I don't speak for ACS). @[email protected], @LaurelOldach in the sky

Articles

  • 3 weeks ago | cen.acs.org | Laurel Oldach

    Six weeks after a reduction in force (RIF) at the US Food and Drug Administration removed thousands of workers, signs are emerging about how the agency's approach to drug approval may change. The 20% RIF on April 1, which excluded drug, device, and food reviewers and inspectors, nonetheless sparked concern and speculation across the pharmaceutical industry.

  • 1 month ago | cen.acs.org | Krystal Vasquez |Laurel Oldach |Britt E. Erickson |Fionna Samuels

    US president Donald J. Trump has proposed massive cuts to federal science programs for fiscal year 2026, which runs from Oct. 1, 2025, through Sept. 30, 2026. The proposal, also referred to as the "skinny" budget because it provides less detail than a full budget request, is in line with Trump's calls during his first term as president to slash funding from the Environmental Protection Agency, the Department of Health and Human Services, and other US federal agencies.

  • 1 month ago | pubs.acs.org | Krystal Vasquez |Laurel Oldach |Britt E. Erickson |Fionna Samuels

    Monday, May 12, 2025 Please be aware that pubs.acs.org is undergoing maintenance from Saturday February 1 to Monday Febraury 3, that may have an impact on your experience. During this time, you may not be able to access certain features like login, purchasing single articles, saving searches or running existing saved searches, modifying your e-Alert preferences, or accessing Librarian administrative functions. We appreciate your patience as we continue to improve the ACS Publications platform.

  • 1 month ago | cen.acs.org | Laurel Oldach

    US Food and Drug Administration layoffs appear to be affecting programs that track drug safety. Fired workers from the Division of Drug Information, which conducts safety monitoring, say the DDI team lost between 75% and 90% of its roughly 50-person staff in the FDA's April 1 reduction in force. "There's a handful of people desperately keeping the lights on," says one fired employee, who like their former colleagues spoke to C&EN on condition of anonymity for fear of repercussions.

  • 1 month ago | cen.acs.org | Laurel Oldach

    Chemists and chemical biologists just keep dreaming up new ways to interfere with biomolecules. That research frequently leads to promising potential medicines, and there are more and more flavors of molecules at some stage of clinical or preclinical investigation. How do drug hunters choose between them? Twenty years ago, monoclonal antibodies were just emerging as a promising type of therapy on the strength of their selective binding to highly specific molecular motifs.

Contact details

Socials & Sites

Try JournoFinder For Free

Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.

Start Your 7-Day Free Trial →

X (formerly Twitter)

Followers
1K
Tweets
4K
DMs Open
No
No Tweets found.